je.st
news
Zacks Gives Neutral Rating to Teva Pharmaceutical Industries Ltd
2013-02-12 11:19:20| Biotech - Topix.net
The firm currently has a $41.00 target price on the stock. Zacks' analyst wrote, "Teva's fourth quarter earnings of $1.32 per American Depositary Share were a penny short of the Zacks Consensus Estimate and 17% below the year-ago earnings.
Tags: rating
ltd
industries
neutral
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||